Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The genetics and biology of KRAS in lung cancer.

Chinese journal of cancer - 1 Feb 2013

Westcott Peter M K, To Minh D

Abstract excerpt

Mutational activation of KRAS is a common oncogenic event in lung cancer and other epithelial cancer types. Efforts to develop therapies that counteract the oncogenic effects of mutant KRAS have been largely unsuccessful, and cancers driven by mutant KRAS remain among the most refractory to available treatments. Studies undertaken over the past decades have produced a wealth of information regarding the clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ras Proteins
Share to RNA, Small Interfering
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Susceptibility

Share to Gene Knockdown Techniques

Share to Genetic Therapy

Share to Neoplasms, Experimental

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 22776234
DOI: 10.5732/cjc.012.10098
PMCID: PMC3845615

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genetics and biology of KRAS in lung cancer.PMID 22776234Read ↗

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Semantic proximity Read ↗

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

KRAS mutations in lung cancer.Semantic proximity Read ↗

KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Semantic proximity Read ↗

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

Pulmonary Inflammation and KRAS Mutation in Lung Cancer.Semantic proximity Read ↗

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.